Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population
- PMID: 25548491
- PMCID: PMC4273143
- DOI: 10.3748/wjg.v20.i47.17932
Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population
Abstract
Aim: To study the prevalence and clinical biochemical, blood cell and metabolic features of lean-non-alcoholic fatty liver disease (lean-NAFLD) and its association with other diseases.
Methods: Demographic, biochemical and blood examinations were conducted in all the subjects in this study. We classified the subjects into four groups according to their weight and NAFLD status: lean-control, lean-NAFLD [body mass index (BMI) < 24 kg/m(2)], overweight-obese control and overweight-obese NAFLD. One-way analysis of variance (ANOVA) was used to compare the means of continuous variables (age, BMI, blood pressure, glucose, lipid, insulin, liver enzymes and blood cell counts) and the χ (2) test was used to compare the differences in frequency of categorical variables (sex, education, physical activity, smoking, alcohol consumption and prevalence of hypertension, hyperlipidemia, diabetes, metabolic syndrome central obesity and obesity). Both univariate and multivariate logistic regression models were adopted to calculate odds ratios (ORs) and predict hyperlipidemia, hypertension, diabetes and metabolic syndrome when we respectively set all controls, lean-control and overweight-obese-control as references. In multivariate logistic regression models, we adjusted potential confounding factors, including age, sex, smoking, alcohol consumption and physical activity.
Results: The prevalence of NAFLD was very high in China. NAFLD patients were older, had a higher BMI, waist circumference, blood pressure, fasting blood glucose, insulin, blood lipid, liver enzymes and uric acid than the controls. Although lean-NAFLD patients had lower BMI and waist circumstance, they had significantly higher visceral adiposity index than overweight-obese controls. Lean-NAFLD patients had comparable triglyceride, cholesterin and low-density lipoprotein cholesterin to overweight-obese NAFLD patients. In blood cell examination, both lean and overweight-obese NAFLD was companied by higher white blood cell count, red blood cell count, hemoglobin and hematocrit value. All NAFLD patients were at risk of hyperlipidemia, hypertension, diabetes and metabolic syndrome (MetS). Lean-NAFLD was more strongly associated with diabetes (OR = 2.47, 95%CI: 1.14-5.35), hypertension (OR = 1.72, 95%CI: 1.00-2.96) and MetS (OR = 3.19, 95%CI: 1.17-4.05) than overweight-obese-NAFLD (only OR for MetS was meaningful: OR = 1.89, 95%CI: 1.29-2.77). NAFLD patients were more likely to have central obesity (OR = 1.97, 95%CI: 1.38-2.80), especially in lean groups (OR = 2.17, 95%CI: 1.17-4.05).
Conclusion: Lean-NAFLD has unique results in demographic, biochemical and blood examinations, and adds significant risk for diabetes, hypertension and MetS in lean individuals.
Keywords: Chinese; Diabetes; Lean-non-alcoholic fatty liver disease; Metabolic disorder; Risk.
Similar articles
-
Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.Vojnosanit Pregl. 2016 Oct;73(10):910-20. doi: 10.2298/VSP150514093P. Vojnosanit Pregl. 2016. PMID: 29327896
-
Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.Clin Gastroenterol Hepatol. 2017 Oct;15(10):1604-1611.e1. doi: 10.1016/j.cgh.2017.04.045. Epub 2017 May 26. Clin Gastroenterol Hepatol. 2017. PMID: 28554682
-
Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients.Aliment Pharmacol Ther. 2017 Jul;46(2):85-95. doi: 10.1111/apt.14112. Epub 2017 May 2. Aliment Pharmacol Ther. 2017. PMID: 28464369 Review.
-
Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population: a prospective cohort study.Atherosclerosis. 2015 May;240(1):144-8. doi: 10.1016/j.atherosclerosis.2015.02.049. Epub 2015 Mar 11. Atherosclerosis. 2015. PMID: 25785362
-
Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese.J Gastroenterol Hepatol. 2012 Oct;27(10):1555-60. doi: 10.1111/j.1440-1746.2012.07222.x. J Gastroenterol Hepatol. 2012. PMID: 22741595 Review.
Cited by
-
Effects of Ganjianglingzhu Decoction on Lean Non-Alcoholic Fatty Liver Disease in Mice Based on Untargeted Metabolomics.Pharmaceuticals (Basel). 2024 Apr 15;17(4):502. doi: 10.3390/ph17040502. Pharmaceuticals (Basel). 2024. PMID: 38675462 Free PMC article.
-
A genetic mouse model of lean-NAFLD unveils sexual dimorphism in the liver-heart axis.Commun Biol. 2024 Mar 22;7(1):356. doi: 10.1038/s42003-024-06035-6. Commun Biol. 2024. PMID: 38519536 Free PMC article.
-
Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis.BMC Med. 2024 Mar 6;22(1):101. doi: 10.1186/s12916-024-03315-0. BMC Med. 2024. PMID: 38448943 Free PMC article.
-
Predictors of High Cardiovascular Risk Among Nonobese Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease in a Chinese Population.Diabetes Metab Syndr Obes. 2024 Feb 1;17:493-506. doi: 10.2147/DMSO.S441641. eCollection 2024. Diabetes Metab Syndr Obes. 2024. PMID: 38318450 Free PMC article.
-
Triglyceride-glucose index is capable of identifying metabolically obese, normal-weight older individuals.J Physiol Anthropol. 2024 Feb 3;43(1):8. doi: 10.1186/s40101-024-00355-6. J Physiol Anthropol. 2024. PMID: 38310267 Free PMC article.
References
-
- Hashimoto E, Taniai M, Tokushige K. Characteristics and diagnosis of NAFLD/NASH. J Gastroenterol Hepatol. 2013;28 Suppl 4:64–70. - PubMed
-
- Preiss D, Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond) 2008;115:141–150. - PubMed
-
- Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686–690. - PubMed
-
- Choi JH, Rhee EJ, Bae JC, Park SE, Park CY, Cho YK, Oh KW, Park SW, Lee WY. Increased risk of type 2 diabetes in subjects with both elevated liver enzymes and ultrasonographically diagnosed nonalcoholic fatty liver disease: a 4-year longitudinal study. Arch Med Res. 2013;44:115–120. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical